QP-Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for Melanoma (Adults)

Description

The Provider Selection Regime (PSR) Competitive Process is being utilised to facilitate the accreditation of suitably qualified providers to establish that they meet the requirements to deliver the Service. For the avoidance of doubt, the services covered in this Competitive Process are not subject to a legal right to patient choice. The key objective of the Competitive Process is to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, initially for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots, to serve the population of England. There is no restriction on the number of sites that will be commissioned, however providers may only bid for one Lot.